Achievement of Minimal Disease Activity and Progression of Radiographic Changes in Early Psoriatic Arthritis One Year After Initiation of Treatment in «treat to Target» Strategy (Preliminary Results of the Remarka Study)

Логинова, Е. Ю.; Коротаева, Т. В.; Смирнов, А. В.; Koltakova, Anastasia; Насонов, Е. Л.

doi:10.14412/1995-4484-2017-610-615

Cited by 5 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Согласно стратегии «Лечение до достижения цели», рекомендуется оценивать эффективность лечения каждые 3-6 мес и при необходимости осуществлять коррекцию терапии [56,69]. Полученные данные согласуются с основными ре-зультатами открытого рандомизированного многоцентрового исследования TICOPA [58,70]. В целом полученные к настоящему времени данные свидетельствуют об эффективности стратегии Т2Т у больных рПсА с применением ГИБП и МТ.…”

unclassified

Psoriatic arthritis: pathogenetic features and innovative therapies

Лила¹,

Насонов

Коротаева³

2019

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

The paper considers the modern concepts of the etiology and pathogenesis of psoriatic arthritis (PsA). The latter is currently indicated as a T-cell-mediated disease that is based on the activation of cellular immunity, followed by the hyperproduction and imbalance of key pro- and anti-inflammatory cytokines, such as tumor necrosis factor-α (TNF- α), interleukin-1β (IL-1β), IL-6, IL-12/23, and IL-17. The paper presents the basic principles of diagnosis and clinical manifestations of the disease and notes the importance of screening questionnaires, the use of which allows specialists to diagnose PsA early, by actively identifying articular complaints, the characteristic clinical and radiological signs of damage to the joint, spine, and entheses. It is pointed out that the key target of pharmacotherapy for PsA is to achieve remission or minimal activity of the main clinical manifestations of the disease, to slow down or prevent its radiographic progression, to increase the length and quality of life in patients, and to reduce the risk of comorbidities. The authors characterize the major groups of used drugs: nonsteroidal anti-inflammatory drugs, conventional and targeted synthetic disease-modifying antirheumatic drugs, and biological drugs (inhibitors of TNF-α, IL-12/23, and IL-17). The key Treat-to-target principles of patient management are considered; it is noted that strict control over disease activity and treatment results provides suppression of all major clinical manifestations of PsA. The paper also shows the basic principles of the creation and further development of the All-Russian Registry of PsA patients, which makes it possible to optimize management decision-making on the provision of high-tech medical care and drugs for this cohort of patients.

show abstract

unclassified

Psoriatic arthritis: pathogenetic features and innovative therapies

Лила¹,

Насонов

Коротаева³

2019

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease)

Абдулганиева¹,

Бакулев²,

Белоусова³

et al. 2018

RJTAO

Self Cite

View full text Add to dashboard Cite

В связи с высоким риском развития у одного пациента нескольких иммунновоспалительных заболеваний (псориаз, псориатический артрит -ПсА и болезнь Крона -БК) крайне актуальными являются их ранняя диагностика и адекватная терапия. Междисциплинарной рабочей группой, в которую вошли эксперты ревматологи, гастроэнтерологи и дерматологи, разработан проект рекомендаций по ранней диагностике, методам оценки активности и показаниям к применению генно-инженерных биологических препаратов у пациентов с сочетанной иммуновоспалительной патологией -псориазом, ПсА, БК. В соответствии с решением Совета экспертов и результатами обсуждения со специалистами из разных регионов Российской Федерации будут предприняты дальнейшие шаги для валидации рекомендаций. Ключевые слова: междисциплинарные рекомендации; псориаз; псориатический артрит; болезнь Крона. Контакты: Татьяна Викторовна Коротаева; tatianakorotaeva@gmail.com; Марианна Михайловна Хобейш; mkhobeysh@yandex.ru; Елена Александровна Белоусова; eabelous@yandex.ru Для ссылки: Абдулганиева ДИ, Бакулев АЛ, Белоусова ЕА и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4-18. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease)Due to that one patient may be at high risk for developing several immunoinflammatory diseases (psoriasis, psoriatic arthritis (PsA), and Crohn's disease (CD)), their early diagnosis and adequate therapy are extremely relevant. The Interdisciplinary Working Group that includes experts in rheumatology, gastroenterology and dermatology has developed draft guidelines for early diagnosis, methods for activity assessments and for indications for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, PsA, and CD).Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генноинженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона) Предпосылки для создания рекомендацийПсориаз, псориатический артрит (ПсА) и воспалительные заболевания кишечника (ВЗК) относятся к многофакторным хроническим иммуновоспалительным потенциально инвалидизирующим заболеваниям, при которых выявляют сходные генетические и иммунологические факторы развития, в частности генетический полиморфизм интерлейкина (ИЛ) 23R, определяющий сигнальный ИЛ12/23-путь иммунопатогенеза [1][2][3][4][5][6].В связи с высоким риском развития у одного пациента нескольких иммуновоспалительных заболеваний, крайне актуальными явл...

show abstract

Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data

Tremaskina¹,

Loginova²,

Коротаева³

et al. 2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to analyze preliminary data on 5-year clinical and radiographic outcomes in patients with early psoriatic arthritis (PsA) observed as part of the Treat to target (T2T) strategy.Patients and methods. We examined 37 patients (18 men and 19 women) with early PsA who met the CASPAR criteria (2006), who received treatment according to the principles of the T2T strategy for 24 months. The mean age of the patients was 43.3±11.7 years, the median (Me) of PsA duration was 72 [60; 90] months, psoriasis – 120 [88; 180] months, follow up – 62 [51; 81] months. After completion of participation in the T2T strategy, patients were followed up in a real clinical setting. Most of the patients used methotrexate, biologic disease modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs. In the dynamics after 5 years, PsA activity was determined by the DAPSA index and the achievement of the minimum disease activity (MiDA). In 16 (43%) patients, a dynamic assessment of radiographic changes in the joints of the hands and feet was performed using the Sharp quantitative method modified for PsA (m-Sharp/vanderHeijde).Results and discussion. By 24 months of therapy (the end of the T2T study), DAPSA remission was registered in 19 (52%) patients, in the same number of cases (16%) low (LDA), moderate (MDA) and high (HDA) disease activity was noted. Me DAPSA was 3.85 [0.67; 21.76], MiDA was detected in 22 (59.5%) patients. After 5 years of observation, Me DAPSA was 7.67 [2.2; 14.5]. Remissions according to DAPSA were achieved in 13 (35%) patients, LDA – also in 13 (35%), MDA – in 5 (14%), HDA remained in 6 (16%), MiDA – in 20 (54%). No significant differences were found when comparing disease activity at 24 months (at the end of the T2T study) and after 5 years of follow-up (p=0.41). In 11 (69%) out of 16 patients after 5 years, a negative trend was recorded in the assessment of radiological progression.Conclusion. After 5 years of follow-up, 70% of patients with PsA treated at an early stage of the disease as part of the T2T strategy achieved remission or LDA, and 54% of patients remained in MiDA. In 69% of patients, despite the achievement of remission and MiDA, there was a negative radiological dynamic in the hands and feet.

show abstract

Achievement of Minimal Disease Activity and Progression of Radiographic Changes in Early Psoriatic Arthritis One Year After Initiation of Treatment in «treat to Target» Strategy (Preliminary Results of the Remarka Study)

Cited by 5 publications

References 15 publications

Psoriatic arthritis: pathogenetic features and innovative therapies

Psoriatic arthritis: pathogenetic features and innovative therapies

Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease)

Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data

Contact Info

Product

Resources

About